Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Recombinant Human Keratinocyte Growth Factor · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Recombinant Human Keratinocyte Growth Factor | DRUG | - |
Inclusion Criteria: \* Patients with: non-Hodgkin's lymphoma, Hodgkin's disease, acute myelogenous leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, or multiple myeloma \* Eligible for fractionated total body irradiation (fTBI) plus high-dose chemoth...
Recombinant Human Keratinocyte Growth Factor is used for stomatitis, specifically to reduce oral mucositis in patients with hematologic malignancies undergoing peripheral blood stem cell transplantation after radiation and high-dose chemotherapy. It is being developed as a treatment for this condition.
Recombinant Human Keratinocyte Growth Factor is being developed by Amgen Inc., a biopharmaceutical company traded on the NASDAQ under the ticker AMGN. The company is conducting clinical research on this drug for the treatment of stomatitis.
Recombinant Human Keratinocyte Growth Factor is in Phase 3 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and efficacy for treating stomatitis.
Recombinant Human Keratinocyte Growth Factor has been studied in a Phase 3 clinical trial registered as NCT00041665. This completed trial evaluated the drug for reducing oral mucositis in patients with hematologic malignancies undergoing peripheral blood stem cell transplantation after radiation and high-dose chemotherapy.
Yes, Recombinant Human Keratinocyte Growth Factor is classified as a small molecule drug. It is being investigated for its potential to treat stomatitis, particularly oral mucositis in patients receiving high-dose chemotherapy and radiation before stem cell transplantation.